ASCO 2021 Lung Cancer In-depth

Liquid Biopsy-Guided Therapy Improves Survival in Lung Cancer

Targeted therapy was associated with better survival with both ctDNA and tissue-only matched patients.

Less Than Half of NSCLC Patients Received Comprehensive Biomarker Testing in a Real-World Study

Most patients had at least 1 biomarker test, but only 46% had all 5 biomarker tests.

Antibody-Drug Conjugate Proves Active in Advanced, Resistant EGFR-Mutated Lung Cancer

Responses were observed across EGFR TKI resistance mechanisms.

Pasireotide Plus Everolimus Improves PFS in Advanced Neuroendocrine Tumors of the Lung or Thymus

The median PFS was 8.5 months in the pasireotide arm, 12.5 months in the everolimus arm, and 16.5 months in the combination arm.

PD-L1 Expression in Macrophage-Like Cells Linked to PFS After Immunotherapy in Non-Small Cell Lung Cancer

The size of cancer-associated macrophage-like cells was linked to progression-free survival as well.

No Survival Difference With Once-Daily vs Twice-Daily Radiotherapy in Small Cell Lung Cancer

Overall and progression-free survival were similar between the treatment arms.